according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
6.0	07/06/2024	28777-00023	Date of first issue: 11/06/2014

### **SECTION 1. IDENTIFICATION**

Product name	:	Posaconazole Suspension Formulation					
Manufacturer or supplier's details							
Company name of supplier	:	Merck & Co., Inc					
Address	:	126 E. Lincoln Avenue					
		Rahway, New Jersey U.S.A. 07065					
Telephone	:	908-740-4000					
Emergency telephone	:	1-908-423-6000					
E-mail address	:	EHSDATASTEWARD@merck.com					
Recommended use of the chemical and restrictions on use							
Recommended use	:	Pharmaceutical					
Restrictions on use	:	Not applicable					

# SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)				
Carcinogenicity (Inhalation)	:	Category 2		
Reproductive toxicity	:	Category 2		
Specific target organ toxicity - repeated exposure (Oral)	:	Category 1 (Adrenal gland, Bone marrow, Kidney, Liver, Nerv- ous system, Reproductive organs)		
GHS label elements Hazard pictograms	:			
Signal Word	:	Danger		
Hazard Statements	:	H351 Suspected of causing cancer if inhaled. H361d Suspected of damaging the unborn child. H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.		
Precautionary Statements	:	<ul> <li>Prevention:</li> <li>P201 Obtain special instructions before use.</li> <li>P202 Do not handle until all safety precautions have been read and understood.</li> <li>P260 Do not breathe mist or vapors.</li> <li>P264 Wash skin thoroughly after handling.</li> <li>P270 Do not eat, drink or smoke when using this product.</li> <li>P280 Wear protective gloves, protective clothing, eye protection and face protection.</li> </ul>		

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:
6.0	07/06/2024	28777-00023

DS Number: Date of last issue: 04/06/2024 Date of first issue: 11/06/2014

## Response:

P308 + P313 IF exposed or concerned: Get medical attention.

#### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

## Other hazards

None known.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)		
Glycerine	56-81-5	>= 10 - < 20		
Posaconazole	171228-49-2	>= 1 - < 5		
Titanium dioxide	13463-67-7	>= 0.1 - < 1		
Actual concentration is withheld as a trade approx				

Actual concentration is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Diarrhea Fever Nausea Headache Vomiting Suspected of causing cancer if inhaled. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed.

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version 6.0	Revision Date: 07/06/2024	-	S Number: 777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
Protection of first-aiders		:	First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8).	
Notes	s to physician	:		natically and supportively.
SECTION	5. FIRE-FIGHTING ME	ASL	IRES	
Suita	ble extinguishing media	:	Water spray Alcohol-resista Carbon dioxide Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
Spec fightir	ific hazards during fire	:	Exposure to co	ombustion products may be a hazard to health.
	rdous combustion prod-	:	Carbon oxides	
Spec ods	ific extinguishing meth-	:	cumstances an Use water spra	ing measures that are appropriate to local cir- nd the surrounding environment. ay to cool unopened containers. maged containers from fire area if it is safe to do
	ial protective equipment e-fighters	:	In the event of	fire, wear self-contained breathing apparatus. protective equipment.

### CTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding

according to the OSHA Hazard Communication Standard



## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
6.0	07/06/2024	28777-00023	Date of first issue: 11/06/2014

certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation Advice on safe handling		Use only with adequate ventilation. Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Posaconazole	171228-49-2	TWA	300 µg/m3 (OEB 2)	Internal
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1

#### Ingredients with workplace control parameters

Engineering measures :	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.
Personal protective equipment	
Respiratory protection :	General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version 6.0	Revision Date: 07/06/2024	SDS Number: 28777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014				
Hand protection Material		unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.					
		: Chemical-resis	stant gloves				
Eye p	rotection	If the work env mists or aeros Wear a facesh	asses with side shields or goggles. vironment or activity involves dusty conditions, ols, wear the appropriate goggles. ield or other full face protection if there is a rect contact to the face with dusts, mists, or				
Skin and body protection Hygiene measures		: If exposure to eye flushing sy working place. When using do Wash contami The effective of engineering co appropriate de industrial hygie	<ul> <li>Work uniform or laboratory coat.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.</li> <li>When using do not eat, drink or smoke.</li> <li>Wash contaminated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</li> </ul>				

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	suspension
Color	:	white
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	4.2 - 4.8
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Ver 6.0	sion	Revision Date: 07/06/2024		S Number: 77-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	)
	Vapor p	pressure	:	No data available	)
	Relative	e vapor density	:	No data available	)
	Relative	e density	:	No data available	)
	Density	,	:	1 g/cm <sup>3</sup>	
	Solubili Wat	ty(ies) er solubility	:	soluble	
	Partitio octanol	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	)
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizii	ng properties	:	The substance of	mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	)
	Particle Particle	e characteristics e size	:	Not applicable	

## SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products	:	None known. Oxidizing agents No hazardous decomposition products are known.

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
6.0	07/06/2024	28777-00023	Date of first issue: 11/06/2014

## SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely rout Inhalation Skin contact Ingestion Eye contact	es of	exposure
Acute toxicity		
Not classified based on ava	ilable	information.
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Components:		
Glycerine:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Guinea pig): > 5,000 mg/kg
Posaconazole:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
		LD50 (Mouse): > 3,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg
Titanium dioxide:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 6.82 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhala- tion toxicity
Skin corrosion/irritation		
Not classified based on ava	liable	information.
<u>Components:</u>		
Glycerine:		
Species Result	:	Rabbit No skin irritation
Posaconazole:		
Species Result	:	Rabbit No skin irritation
		7 / 19

according to the OSHA Hazard Communication Standard



# **Posaconazole Suspension Formulation**

abbit o skin irritation ormation. abbit o eye irritation
o skin irritation ormation. abbit o eye irritation
o skin irritation ormation. abbit o eye irritation
abbit o eye irritation abbit
abbit o eye irritation abbit
o eye irritation abbit
o eye irritation abbit
o eye irritation abbit
abbit
ild eye irritation
abbit
o eye irritation
ormation.
ormation.
agnusson-Kligman-Test kin contact
uinea pig
egative
egative
ocal lymph node assay (LLNA)

Not classified based on available information.

### Components:

**Glycerine:** 

according to the OSHA Hazard Communication Standard



ersion D	Revision Date: 07/06/2024	SDS Number: 28777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
Geno	toxicity in vitro	: Test Type: I Result: nega	n vitro mammalian cell gene mutation test ttive
		Test Type: E Result: nega	Bacterial reverse mutation assay (AMES)
		Test Type: 0 Result: nega	Chromosome aberration test in vitro
			DNA damage and repair, unscheduled DNA syn- mmalian cells (in vitro) ative
Posa	conazole:		
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES)
		Test Type: 0 Result: nega	Chromosomal aberration ative
Geno	toxicity in vivo	Species: Mc Cell type: Bc	one marrow Route: Intravenous
Titani	ium dioxide:		
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES) ative
	toxicity in vivo	: Test Type: I Species: Mo Result: nega	
II Carci	nogenicity		
Suspe	ected of causing cano	er if inhaled.	
<u>Comp</u>	oonents:		
Glyce			
Speci Applic	es cation Route	: Rat : Ingestion	
Expos	sure time	: 2 Years	
Resul	t	: negative	
Posa	conazole:		
Speci		: Rat	
	cation Route sure time	: oral (feed) : 2 Years	
Resul		: positive	
Rema	ırks		ism or mode of action is not relevant in humans

according to the OSHA Hazard Communication Standard



rsion	Revision D 07/06/2024			S Number: 777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
Specie Applic Expos Result Rema	ation Route sure time t		:	Mouse Oral 2 Years positive The mechanism	or mode of action is not relevant in humans
Titani	um dioxide:				
	ation Route sure time od t			Rat inhalation (dust/r 2 Years OECD Test Guid positive The mechanism mans.	
Carcir ment	nogenicity - A	SSESS-	:	Limited evidence animals.	e of carcinogenicity in inhalation studies with
IARC		oup 2B: Pos anium dioxid		ly carcinogenic to	humans 13463-67-7
II OSHA				this product prese regulated carcino	ent at levels greater than or equal to 0.1% is
					gens.
NTP		ingredient of	of tł	nis product preser	nt at levels greater than or equal to 0.1% is I carcinogen by NTP.
Repro Suspe <u>Comp</u> Glyce	ide oductive toxi acted of dama ponents:	ingredient o ntified as a <b>city</b>	of tl kno	nis product preser own or anticipated	nt at levels greater than or equal to 0.1% is I carcinogen by NTP.
Repro Suspe <u>Comp</u> Glyce Effects	ide oductive toxi ected of dama oonents: prine:	ingredient o ntified as a <b>city</b> aging the un	of tl kno	nis product preser own or anticipated rn child. Test Type: Two- Species: Rat Application Rout Result: negative	nt at levels greater than or equal to 0.1% is I carcinogen by NTP. generation reproduction toxicity study e: Ingestion yo-fetal development
Repro Suspe <u>Comp</u> Glyce Effects	ide oductive toxi ected of dama <u>ponents:</u> srine: s on fertility	ingredient o ntified as a <b>city</b> aging the un	of tl kno	nis product preser own or anticipated own or anticipated own or anticipated own or anticipated transformatic Species: Rat Application Rout Species: Rat Application Rout	nt at levels greater than or equal to 0.1% is I carcinogen by NTP. generation reproduction toxicity study e: Ingestion yo-fetal development
Repro Suspe Comp Glyce Effects Effects	ide oductive toxi ected of dama <u>conents:</u> s on fertility s on fertility	ingredient o ntified as a <b>city</b> aging the un	of tl kno	nis product preser own or anticipated in child. Test Type: Two- Species: Rat Application Rout Result: negative Test Type: Embr Species: Rat Application Rout Result: negative Test Type: Fertil Species: Rat, ma General Toxicity	at at levels greater than or equal to 0.1% is l carcinogen by NTP. generation reproduction toxicity study e: Ingestion yo-fetal development e: Ingestion

according to the OSHA Hazard Communication Standard



## **Posaconazole Suspension Formulation**

Versio 6.0	on Revision Date: 07/06/2024		DS Number: 777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
				ale Parent: NOAEL: 45 mg/kg body weight fects on mating performance.
E	Effects on fetal development		Test Type: Embryo-fetal development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity., Malformations were observed.	
			Species: Rabbit,	oxicity: LOAEL: 40 mg/kg body weight
	Reproductive toxicity - As- essment	:	Some evidence o animal experimer	f adverse effects on development, based on its.

### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

#### **Components:**

#### Posaconazole:

Routes of exposure Target Organs	: Ingestion
Target Organs	: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive
	organs, Nervous system
Assessment	: Causes damage to organs through prolonged or repeated
	exposure.

#### **Repeated dose toxicity**

#### **Components:**

#### Glycerine:

Species NOAEL LOAEL	:	Rat 0.167 mg/l 0.622 mg/l
Application Route Exposure time	:	inhalation (dust/mist/fume)
Species NOAEL Application Route Exposure time		Rat 8,000 - 10,000 mg/kg Ingestion 2 y
Species NOAEL Application Route		Rabbit 5,040 mg/kg Skin contact

according to the OSHA Hazard Communication Standard



Version 6.0	Revision Date: 07/06/2024	SDS Number: 28777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
Expos	ure time	: 45 Weeks	
Posac	onazole:		
Expos		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal gland	d, Lungs, Heart, Liver, spleen, Kidney, Ovary
Expos		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lympho	Brain, small intestine, Adrenal gland, Spinal id tissue
Expos		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrow	v, Adrenal gland, Lymph nodes, Blood
Expos			d, Bone marrow, Kidney, Nervous system, us gland, Testis, lymphoid tissue
Expos		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastro	pintestinal tract, spleen
Expos	es L ation Route ure time t Organs	: Monkey : 8 mg/kg : Intravenous : 1 Months : Cardio-vascu	ılar system, Lungs, Adrenal gland, Blood
Titanio	um dioxide:		
		: Rat : 24,000 mg/kg : Ingestion : 28 Days	)
		: Rat : 10 mg/m³ : inhalation (du : 2 y	ust/mist/fume)

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
6.0	07/06/2024	28777-00023	Date of first issue: 11/06/2014

### Aspiration toxicity

Not classified based on available information.

## Experience with human exposure

### **Components:**

#### Posaconazole:

Ingestion

: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

### Components:

Glycerine:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1,955 mg/l Exposure time: 48 h
Toxicity to microorganisms	:	NOEC (Pseudomonas putida): > 10,000 mg/l Exposure time: 16 h Method: DIN 38 412 Part 8
Posaconazole:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic	:	EC50 (Pseudokirchneriella subcapitata (green algae)): >

l oxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox- icity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l Exposure time: 33 d Method: OECD Test Guideline 210

according to the OSHA Hazard Communication Standard



Versior 6.0	n	Revision Date: 07/06/2024		9S Number: 777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
ac		to daphnia and other invertebrates (Chron- ty)	:	Exposure time: 21 Method: OECD To	
Τc	oxicity	to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD To	ation inhibition
II Ti	itaniu	m dioxide:			
		to fish	:	LC50 (Oncorhync Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): > 100 mg/l 3 h
	oxicity ants	to algae/aquatic	:	EC50 (Skeletoner Exposure time: 72	ma costatum (marine diatom)): > 10,000 mg/l 2 h
Тс	oxicity	to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Method: OECD Te	h
Pe	ersist	ence and degradabili	ty		
<u>Co</u>	ompo	onents:			
G	lyceri	ne:			
Bi	iodegr	radability	:	Result: Readily bi Biodegradation: 9 Exposure time: 30 Method: OECD To	92 %
Po	osaco	onazole:			
Bi	iodegr	adability	:	Result: Not readily Biodegradation: 5 Exposure time: 28 Method: OECD Te	50 % 3 h
St	tability	in water	:	Degradation half I Method: OECD Te	
Bi	ioacc	umulative potential			
<u>Co</u>	ompo	onents:			
G	lyceri	ne:			
		n coefficient: n- /water	:	log Pow: -1.75	

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version 6.0	Revision Date: 07/06/2024		DS Number: 3777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
Posa	conazole:			
Bioac	cumulation	:	Bioconcentration	s macrochirus (Bluegill sunfish) factor (BCF): 20 est Guideline 305
	Partition coefficient: n- octanol/water		log Pow: 4.15	
Mobil	ity in soil			
Comp	oonents:			
Distrik	<b>conazole:</b> oution among environ- al compartments	:	log Koc: 5.52	
•	<b>adverse effects</b> Ita available			
SECTION	13. DISPOSAL CONSI	DEF	RATIONS	

Disposal methods		
Waste from residues	: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.	
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste handling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>	

### **SECTION 14. TRANSPORT INFORMATION**

### International Regulations

UNRTDG		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Posaconazole)
Class	:	9
Packing group	:	
Labels	:	9
Environmentally hazardous	:	yes
IATA-DGR		
UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Posaconazole)
Class	:	9
Packing group	:	
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passen- ger aircraft)	:	964
Environmentally hazardous	:	yes

according to the OSHA Hazard Communication Standard



## **Posaconazole Suspension Formulation**

Version 6.0	Revision Date: 07/06/2024	SDS Number: 28777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
UN n Prope Class Packi Label EmS	ing group Is Code	N.O.S. (Posaconaz : 9 : III : 9 : F-A, S-F	ENTALLY HAZARDOUS SUBSTANCE, LIQUID, ole)
	e pollutant	: yes	IARPOL 73/78 and the IBC Code
	pplicable for product	•	TARY OF 75/70 and the IBC Code
Dom	estic regulation		
Prope Class Packi Label ERG Marin Rema	D/NA number er shipping name ing group Is Code ne pollutant	(Posaconaz 9 111 CLASS 9 171 yes(Posaco Above appli liters. Shipment by may be ship facilitate mu	, ,

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### **SECTION 15. REGULATORY INFORMATION**

#### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	: Carcinogenicity
	Reproductive toxicity
	Specific target organ toxicity (single or repeated exposure)

according to the OSHA Hazard Communication Standard



# Posaconazole Suspension Formulation

Version 6.0	Revision Date: 07/06/2024	SDS Number: 28777-00023	Date of last issue: 04/06/2024 Date of first issue: 11/06/2014
SAR	A 313	known CAS n	does not contain any chemical components with umbers that exceed the threshold (De Minimis) Is established by SARA Title III, Section 313.
US S	tate Regulations		
Penn	sylvania Right To K	now	
	Water Glucose Glycerine Posaconazole		7732-18-5 50-99-7 56-81-5 171228-49-2
WAR know		ornia to cause cancer	micals including Titanium dioxide, which is/are . For more information go to
Califo	ornia Permissible Ex	posure Limits for C	hemical Contaminants
	Glycerine		56-81-5
The i	ngredients of this p	roduct are reported i	in the following inventories:
AICS		: not determine	d
DSL		: not determine	d
IECS	с	: not determine	d


### **SECTION 16. OTHER INFORMATION**

**Further information** 



according to the OSHA Hazard Communication Standard

## Posaconazole Suspension Formulation



### Full text of other abbreviations

OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-
		its for Air Contaminants
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response: ERG - Emergency Response Guide: GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity: SADT - Self-Accelerating Decomposition Temperature: SARA - Superfund Amend-

according to the OSHA Hazard Communication Standard



## Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
6.0	07/06/2024	28777-00023	Date of first issue: 11/06/2014

ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Revision Date	:	07/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8